Look Forward – Summer 2026 – Issue 190
Our young adults got to grips with white water rafting recently, building confidence and resilience while having fun.
Search
Search results
Corporate partnerships
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
Oxfordshire information event (online)
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
Sirius clinical trial – Exon 13 mutation of USH2A
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
CRISPR Gene Editing Leads to Improvements
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.
Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Webinar: Ask the Expert: Dr Roly Megaw
This time we are joined by Roly Megaw, Clinical Lecturer and Honorary Consultant Ophthalmologist at University of Edinburgh and NHS Lothian
Webinar: Ask the expert with Professor Marcela Votruba
The latest webinar from Retina UK.
Renewed Momentum for XLRP: MeiraGTx Targets Rapid Approval Path for bota-vec following reacquisition from Johnson and Johnson
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.
Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.